David P Schenkein
CIK 1578200 · Chief Executive Officer · last filed 2026-06-08
David P Schenkein is a Chief Executive Officer who has filed 130 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing, for PRME, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$70.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.6M across reported positions. 12 SEC filings were submitted jointly with bluebird bio, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGIO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRME | Director | — | $5.36 | — | $0 | 5 | 2026-06-08 |
| DNLI | Director | 52,897 | $19.29 | $1.02M | -$7.84M | 17 | 2026-06-05 |
| REGN | Director | 603 | $813.27 | $490.4K | $0 | 4 | 2026-01-06 |
| AGIO | Director | 397,014 | $38.12 | $15.13M | -$62.02M | 86 | 2024-06-24 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 342 | $4.97 | $1.7K | -$577.8K | 10 | 2020-06-22 |
| Foundation Medicine, Inc. (FMI) Delisted | Director | 28,580 | — | — | $0 | 5 | 2016-06-20 |
Recent Filings
130 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | PRME | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | DNLI | Grant (A) | +6,408 | $0 | EDGAR |
| 2026-01-06 | REGN | Grant (A) | +155 | $0 | EDGAR |
| 2025-08-05 | PRME | Mixed | — | $0 | EDGAR |
| 2025-06-05 | DNLI | Grant (A) | +6,037 | $0 | EDGAR |
| 2025-06-05 | PRME | Grant (A) | — | $0 | EDGAR |
| 2025-01-06 | REGN | Grant (A) | +166 | $0 | EDGAR |
| 2024-11-13 | DNLI | Mixed | −12,276 | -$1.08M | EDGAR |
| 2024-11-12 | DNLI | Notice (144) | −59,441 | -$1.86M | EDGAR |
| 2024-06-24 | AGIO | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.